PolarCools progress continues in Swiss ice hockey – HC Ajoie signs agreement

The med-tech company PolarCool AB (publ.) continues its strategic growth initiatives for PolarCap® in European ice hockey, by signing an agreement with Swiss professional ice hockey team HC Ajoie.

PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® System include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

PolarCool has established strategic collaborations in Swiss ice hockey with professional clubs HC Davos and HC Lugano, and HC Ajoie join their league counterparts by adding treatment with the PolarCap® System into their concussion management routines.

PolarCool CEO Erik Andersson comments:

-We view the recent sales progress very positively and I am pleased that yet another top ice hockey club has chosen to sign an agreement for the use of the PolarCap® System. We foresee that the increased awareness of our treatment method provides opportunities for further agreements in this market.

The agreement with HC Ajoie reflects PolarCool's overall strategy to introduce PolarCap® to the international ice hockey market and marks important strategic progress for PolarCool even if the financial impact of individual agreements is limited.

For more information

Erik Andersson –  CEO PolarCool AB (publ.)               
+46 - 738 60 57 00                                         
E-mail: erik.andersson@polarcool.se 

About PolarCool AB (publ.)

PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.